News
FDA, COPD and Nucala
Digest more
Medpage Today on MSN23h
FDA Approves Mepolizumab for COPDMepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...
A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...
Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...
FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
MedPage Today on MSN6d
Adding CT, Symptoms Improves COPD DiagnosisThe schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...
We have developed a new, multidimensional diagnostic schema for COPD that incorporates spirometry, symptoms, and imaging and ...
New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...
Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...
Eucalyptus oil was first used by Aboriginal Australians, who crushed the leaves for their antiseptic properties or steamed ...
The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback